Literature DB >> 11418606

Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity.

J Boncela1, I Papiewska, I Fijalkowska, B Walkowiak, C S Cierniewski.   

Abstract

alpha(1)-Acid glycoprotein, one of the major acute phase proteins, was found to interact with plasminogen activator inhibitor type 1 (PAI-1) and to stabilize its inhibitory activity toward plasminogen activators. This conclusion is based on the following observations: (a) alpha(1)-acid glycoprotein was identified to bind PAI-1 by a yeast two-hybrid system. Three of 10 positive clones identified by this method to interact with PAI-1 contained almost the entire sequence of alpha(1)-acid glycoprotein; (b) this protein formed complexes with PAI-1 that could be immunoprecipitated from both the incubation mixtures and blood plasma by specific antibodies to either PAI-1 or alpha(1)-acid glycoprotein. Such complexes could be also detected by a solid phase binding assay; and (c) the real-time bimolecular interactions monitored by surface plasmon resonance indicated that the complex of alpha(1)-acid glycoprotein with PAI-1 is less stable than that formed by vitronectin with PAI-1, but in both cases, the apparent K(D) values were in the range of strong interactions (4.51 + 1.33 and 0.58 + 0.07 nm, respectively). The on rate for binding of PAI-1 to alpha(1)-glycoprotein or vitronectin differed by 2-fold, indicating much faster complex formation by vitronectin than by alpha(1)-acid glycoprotein. On the other hand, dissociation of PAI-1 bound to vitronectin was much slower than that from the alpha(1)-acid glycoprotein, as indicated by 4-fold lower k(off) values. Furthermore, the PAI-1 activity toward urokinase-type plasminogen activator and tissue-type plasminogen activator was significantly prolonged in the presence of alpha(1)-acid glycoprotein. These observations suggest that the complex of PAI-1 with alpha(1)-acid glycoprotein can play a role as an alternative reservoir of the physiologically active form of the inhibitor, particularly during inflammation or other acute phase reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418606     DOI: 10.1074/jbc.M104028200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Meta-analysis of genome-wide association studies of aggressive and chronic periodontitis identifies two novel risk loci.

Authors:  Matthias Munz; Gesa M Richter; Bruno G Loos; Søren Jepsen; Kimon Divaris; Steven Offenbacher; Alexander Teumer; Birte Holtfreter; Thomas Kocher; Corinna Bruckmann; Yvonne Jockel-Schneider; Christian Graetz; Ilyas Ahmad; Ingmar Staufenbiel; Nathalie van der Velde; André G Uitterlinden; Lisette C P G M de Groot; Jürgen Wellmann; Klaus Berger; Bastian Krone; Per Hoffmann; Matthias Laudes; Wolfgang Lieb; Andre Franke; Jeanette Erdmann; Henrik Dommisch; Arne S Schaefer
Journal:  Eur J Hum Genet       Date:  2018-09-14       Impact factor: 4.246

2.  Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.

Authors:  Yuzhuo Chu; Joel C Bucci; Cynthia B Peterson
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

3.  Plasminogen activator inhibitor type 1 interacts with alpha3 subunit of proteasome and modulates its activity.

Authors:  Joanna Boncela; Patrycja Przygodzka; Izabela Papiewska-Pajak; Elzbieta Wyroba; Magdalena Osinska; Czeslaw S Cierniewski
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

4.  Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea.

Authors:  David Gozal; Saeed Jortani; Ayelet B Snow; Leila Kheirandish-Gozal; Rakesh Bhattacharjee; Jinkwan Kim; Oscar Sans Capdevila
Journal:  Am J Respir Crit Care Med       Date:  2009-09-24       Impact factor: 21.405

5.  In vivo clearance of alpha-1 acid glycoprotein is influenced by the extent of its N-linked glycosylation and by its interaction with the vessel wall.

Authors:  Teresa R McCurdy; Varsha Bhakta; Louise J Eltringham-Smith; Sharon Gataiance; Alison E Fox-Robichaud; William P Sheffield
Journal:  J Biomed Biotechnol       Date:  2012-04-01

Review 6.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

7.  Fibroblast growth factor-2 did not restore plasminogen system activity in endothelial cells on glycated collagen.

Authors:  Justin George Mathew; Alisa Morss Clyne
Journal:  Biochem Biophys Rep       Date:  2015-09-03

Review 8.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

9.  Different glycoforms of alpha-1-acid glycoprotein contribute to its functional alterations in platelets and neutrophils.

Authors:  Mosale Seetharam Sumanth; Shancy P Jacob; Kandahalli Venkataranganayaka Abhilasha; Bhanu Kanth Manne; Venkatesha Basrur; Sylvain Lehoux; Robert A Campbell; Christian C Yost; Thomas M McIntyre; Richard D Cummings; Andrew S Weyrich; Matthew T Rondina; Gopal K Marathe
Journal:  J Leukoc Biol       Date:  2020-10-18       Impact factor: 4.962

10.  Transcriptional events during the recovery from MRSA lung infection: a mouse pneumonia model.

Authors:  Jiwang Chen; Gang Feng; Qiang Guo; Juliane B Wardenburg; Simon Lin; Ichiro Inoshima; Ryan Deaton; Jason X J Yuan; Joe G N Garcia; Roberto F Machado; Michael Otto; Richard G Wunderink
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.